PLX Stock — Protalix Biotherapeutics Inc

Protalix Biotherapeutics Inc (PLX)

Updated October 16, 2026.

PLX is a Stock. Total return is -99.6% over the past 30.5 years, 2010.7 points behind SPY at 1911.1%.

Protalix BioTherapeutics is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins using its proprietary plant cell-based ProCellEx expression system. The company markets Elelyso for Gaucher disease and Elfabrio for Fabry disease, with additional candidates in development for gout and other conditions, supported by partnerships including one with Pfizer. The company does not currently distribute to shareholders.

PLX performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.6% over the past 30.5 years, 2010.7 points behind SPY at 1911.1%. Over the past year its total return — price change plus distributions reinvested — is 9.2%. Its deepest 1-year drawdown was 39.7%.

PLX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/09/1996

Distribution frequency

None

Last close

$2.62 (as of 2026-10-16)

Market cap

$211,097,702

Average volume

1184747.0

Payment date

12/20/2019

Beta

-0.088

Payout ratio

0.0%

P/E ratio

11.39

Forward P/E

55.8659

EPS

$0.23

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PLX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.7%.

Who may consider PLX — and who may not

It is a weaker fit for investors who need monthly cash flow (PLX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PLX

• All tickers starting with P

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions